

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS II LLC
Petitioner

v.

NPS PHARMACEUTICALS, INC.
Patent Owner

Case No. IPR2015-01093
Patent No. 7,056,886

PETITIONER'S UPDATED EXHIBIT LIST

EXHIBIT	DESCRIPTION	FILED
1001	Declaration of Dr. Anthony Palmieri III, Ph.D., R.Ph.	<input checked="" type="checkbox"/>
1002	CV of Dr. Palmieri	<input checked="" type="checkbox"/>
1003	U.S. Patent No. 7,056,886 to Isaacs	<input checked="" type="checkbox"/>
1004	U.S. Patent Application Ser. No. 09/750,022	<input checked="" type="checkbox"/>
1005	U.S. Patent No.5,496,801 to Holthuis <i>et al.</i>	<input checked="" type="checkbox"/>
1006	U.S. Patent No.6,120,761 to Yamazaki <i>et al.</i>	<input checked="" type="checkbox"/>
1007	March 8, 2002 Non Final Office Action	<input checked="" type="checkbox"/>
1008	June 10, 2002 Amendment and Reply	<input checked="" type="checkbox"/>
1009	February 5, 2003 Non Final Office Action	<input checked="" type="checkbox"/>
1010	July 9, 2003 Amendment and Reply	<input checked="" type="checkbox"/>
1011	September 16, 2003 Non Final Office Action	<input checked="" type="checkbox"/>
1012	March 16, 2004 Amendment and Reply	<input checked="" type="checkbox"/>
1013	June 8, 2004 Final Office Action	<input checked="" type="checkbox"/>
1014	September 7, 2004 Amendment and Reply	<input checked="" type="checkbox"/>
1015	October 4, 2004 Non Final Office Action	<input checked="" type="checkbox"/>
1016	January 4, 2005 Amendment and Reply	<input checked="" type="checkbox"/>
1017	April 4, 2005 Notice of Allowance and Fee(s) Due	<input checked="" type="checkbox"/>
1018	Kieffer & Habener, The Glucagon-Like Peptides, Endocrine Reviews 20(6): 876-913 (1999)	<input checked="" type="checkbox"/>
1019	Lomize <i>et al.</i> , Thermodynamic Model of Secondary Structure for α -Helical Peptides and Proteins, Biopolymers 42:239 (1997)	<input checked="" type="checkbox"/>
1020	Dacambra <i>et al.</i> , Structural Determinants for Activity of Glucagon-like Peptide-2. Biochemistry 39:8888-8894 (July	<input checked="" type="checkbox"/>

	2000)	
1021	Drucker <i>et al.</i> , Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV, Nat. Biotechnol. 15(7):673-7. (July 1997)	<input checked="" type="checkbox"/>
1022	Munroe <i>et al.</i> , Prototypic G-protein coupled receptor for the intestinotrophic factor glucagon –like peptide 2, Proc. Nat’l Acad. Sci. 96:1569 (1999)	<input checked="" type="checkbox"/>
1023	Drucker <i>et al.</i> , Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis, Am J. Physiology 276:G79 (1999)	<input checked="" type="checkbox"/>
1024	Cleland <i>et al.</i> , Formulation and Delivery of Proteins and Peptides, American Chemical Society, Washington D.C., Chapter 1 (1994)	<input checked="" type="checkbox"/>
1025	WO 99/043361 to Knudsen	<input checked="" type="checkbox"/>
1026	U.S. Patent No. 4,985,244 to Makino	<input checked="" type="checkbox"/>
1027	U.S. Patent No. 5,652,216 to Kornfelt <i>et al.</i>	<input checked="" type="checkbox"/>
1028	PCT Publication WO98/52600	<input checked="" type="checkbox"/>
1029	U.S. Patent No. 5,789,379 to Drucker <i>et al.</i>	<input checked="" type="checkbox"/>
1030	Osterberg <i>et al.</i> , Physical state of L-histidine after freeze-drying and long-term storage, EP. J. of Pharm. Sci. 1999 Aug., 8:301-308.	<input checked="" type="checkbox"/>
1031	<i>Intentionally Left Blank</i>	---
1032	Shire Development IPR Petition	<input checked="" type="checkbox"/>
1033	Shire Federal Circuit Brief	<input checked="" type="checkbox"/>
1034	Declaration of Brent Routman in Support of Petitioner’s Motion for Admission <i>Pro Hac Vice</i>	<input checked="" type="checkbox"/>
1035	NPS Pharmaceuticals, Inc., Annual Report (Form 10-K)	<input checked="" type="checkbox"/>

	(February 18, 2015)	
1036	Declaration of Professor Marc I. Steinberg, J.D., LL.M.	<input checked="" type="checkbox"/>
1037	Joint letter from AARP, AHIP, BCBSA and PCMA to Chairmen Grassley and Goodlatte and Ranking Members Leahy and Conyers (July 9, 2015)	<input checked="" type="checkbox"/>
1038	Dean Baker, The Impact of Exempting the Pharmaceutical Industry from Patent Reviews, Center for Economic and Policy Research (July, 2015)	<input checked="" type="checkbox"/>
1039	Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, Gattex	<input checked="" type="checkbox"/>
1040	Matthew Herper, Inside the Pricing of a \$300,000-A-Year Drug, Forbes (January 3, 2013)	<input checked="" type="checkbox"/>
1041	Reply Declaration of Anthony Palmieri III, Ph.D., R.Ph.	<input checked="" type="checkbox"/>
1042	Reply Declaration of Ivan Hofmann (Confidential)	<input checked="" type="checkbox"/>
1043	Deposition Transcript of Dr. John Carpenter, dated March 30, 2016	<input checked="" type="checkbox"/>
1044	Dr. John Carpenter Deposition Exhibit No. 102	<input checked="" type="checkbox"/>
1045	Dr. John Carpenter Deposition Exhibit No. 104	<input checked="" type="checkbox"/>
1046	Dr. John Carpenter Deposition Exhibit No. 105	<input checked="" type="checkbox"/>
1047	Dr. John Carpenter Deposition Exhibit No. 108	<input checked="" type="checkbox"/>
1048	Dr. John Carpenter Deposition Exhibit No. 109	<input checked="" type="checkbox"/>
1049	Dr. John Carpenter Deposition Exhibit No. 110	<input checked="" type="checkbox"/>
1050	Dr. John Carpenter Deposition Exhibit No. 111	<input checked="" type="checkbox"/>
1051	Manning et al., 1989 Pharm. Res. 6, 903-918	<input checked="" type="checkbox"/>
1052	Linde et al., Journal of Chromatography, 530:29-37 (1990)	<input checked="" type="checkbox"/>
1053	Yahoo Finance, NBI Pharmaceuticals historical monthly stock prices, 2012-2015 (http://finance.yahoo.com/q/hp?s=%5ENBI&a=09&b=1&c=2012&d=01&e=2&f=2015&g=m)	<input checked="" type="checkbox"/>
1054	Shire to Acquire NPS Pharmaceuticals for \$5.2B – Nasdaq Analyst Blog (http://www.nasdaq.com/article/shire-to-acquire-nps-pharmaceuticals-for-52b-analyst-blog-cm432089)	<input checked="" type="checkbox"/>
1055	Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech – Shire	<input checked="" type="checkbox"/>

	Newsroom(https://www.shire.com/newsroom/2015/january/shire-to-acquire-nps-pharma-as-further-step-in-building-a-leading-biotech)	
1056	Shire, 2015, “Shire to acquire NPS Pharmaceuticals” Presentation (January 11, 2015)	<input checked="" type="checkbox"/>
1057	Shire, Half Yearly Report 2015 (http://investors.shire.com/~media/Files/S/Shire-IR/annual-interim-reports/year-2015/half-yearly-report-july-2015-v1.pdf)	<input checked="" type="checkbox"/>
1058	Shire, 2015, “Shire to acquire NPS Pharmaceuticals” Call Transcript (January 11, 2015)	<input checked="" type="checkbox"/>
1059	Shire, 2015 Form 10-K	<input checked="" type="checkbox"/>
1060	Gattex, “About Gattex.” (https://www.gattex.com/about-gattex.aspx)	<input checked="" type="checkbox"/>
1061	Gattex, “Why Choose Gattex?” (https://www.gattex.com/getting-started/why-choose-gattex.aspx)	<input checked="" type="checkbox"/>
1062	Shire 2014 Annual Report	<input checked="" type="checkbox"/>
1063	Shire, 2016, “Creating the global leader in Rare Diseases; Fourth quarter and full year results to December 31, 2015” (February 11, 2016)	<input checked="" type="checkbox"/>
1064	NPS, 2012, “FDA Approves Gattex [®] (teduglutide [rDNA Origin]) for Injection for the Treatment of Adult Short Bowel Syndrome” (December 21, 2012) (http://ir.npsp.com/releasedetail.cfm?releaseid=830142)	<input checked="" type="checkbox"/>
1065	OnePath, https://www.shire.com/patients/patient-services/onepath	<input checked="" type="checkbox"/>
1066	Gattex, “Patient Support.” (https://www.gattex.com/patient-support.aspx)	<input checked="" type="checkbox"/>
1067	FDA: Search Orphan Drug Designations and Approvals (https://www.accessdata.fda.gov/scripts/opdlisting/oopd/OPD_Results_2.cfm)	<input checked="" type="checkbox"/>
1068	Fox Business “Why One Drug Costs \$295K a Year” January 24, 2013. (http://www.foxbusiness.com/features/2013/01/24/why-one-drug-costs-25k-year.html)	<input checked="" type="checkbox"/>
1069	FDA: Frequently Asked Questions (FAQ) Regarding Designating an Orphan Product (http://www.fda.gov/ForIndustry/DevelopingProductsforRa)	<input checked="" type="checkbox"/>

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.